VJDementia is committed to improving our service to you

VJVirtual | CT1812: exciting preliminary results

VJDementia is committed to improving our service to you

Susan Catalano

Susan Catalano, PhD, of Cognition Therapeutics Inc., Pittsburgh, PA, gives us an update on the drug candidate CT1812. Dr Catalano discusses data from the Phase II SHINE trial (NCT03507790) evaluating the safety and efficacy of CT1812 in patients with mild to moderate Alzheimer’s Disease. Additionally, CT1812 is currently in multiple phase II clinical trials in Alzheimer’s patients (NCT03522129, NCT03493282). This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).

Share this video